Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • uniQure News

    4,67 $ -0,85% -0,04 $
    In : 4,3823 € | 19.04.24 22:00:00 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A1XDTV
    ISIN: NL0010696654
    US-Symbol: QURE
    Typ: Aktie

    uniQure News

    28.02.24 - GlobeNewswire
    uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
    ~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease; Up to three years of follow-up data to be presented in mid-2024; ...
    15.01.24 - PR Newswire
    Swissmedic erteilt Zulassung für CSLs HEMGENIX® (Etranacogene Dezaparvovec) als erste Gentherapie für Hämophilie B
    Swissmedic erteilt Zulassung für CSLs HEMGENIX® (Etranacogene Dezaparvovec) als erste Gentherapie für Hämophilie B PR Newswire
    19.12.23 - GlobeNewswire
    uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
    ~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-​dependent clinical benefits relative to an inclusion criteria-​matched ...
    11.12.23 - PR Newswire
    CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B
    CSL Behring's HEMGENIX® (etranacogene dezaparvovec-​drlb) Demonstrates at Three Years Post-​Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus ...
    08.12.23 - GlobeNewswire
    uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    LEXINGTON, Mass. and AMSTERDAM, Dec. 08, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies ...
    29.11.23 - GlobeNewswire
    uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
    Patient enrollment expected to begin in first half of 2024
    07.11.23 - GlobeNewswire
    uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
    ~ Announced FDA clearance of Investigational New Drug (IND) application for AMT-260 in  refractory mesial temporal lobe epilepsy ~
    27.10.23 - PR Newswire
    CSL and uniQure Win 2023 Prix Galien USA Award
    CSL and uniQure Win 2023 Prix Galien USA Award PR Newswire
    24.10.23 - GlobeNewswire
    uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
    LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies ...
    05.10.23 - GlobeNewswire
    uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
    ~ Reduction of 28% of workforce not related to HEMGENIX ® manufacturing obligations; Total cost savings of $180 million to extend cash runway into second quarter of 2027 ~ ~ ...
    02.10.23 - GlobeNewswire
    uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    LEXINGTON, Mass. and AMSTERDAM, Oct. 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies ...
    05.09.23 - GlobeNewswire
    uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
    Clinical trial initiation expected in the fourth quarter of 2023
    01.09.23 - PR Newswire
    Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600
    Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 PR Newswire
    01.08.23 - GlobeNewswire
    uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
    ~ Announced encouraging interim analysis data from ongoing Phase I/II clinical trial of AMT-130 in Huntington’s disease showing preservation of function compared to baseline and ...
    26.06.23 - GlobeNewswire
    uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
    ~ Walid Abi-Saab, M.D., appointed Chief Medical Officer, will bring extensive track record in leading drug development and execution ~
    21.06.23 - GlobeNewswire
    uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
    ~ AMT-130 continues to be generally well-​tolerated across both dose cohorts ~
    21.06.23 - PR Newswire
    Thinking about buying stock in Eightco Holdings, Uniqure, Atento, Red Cat Holdings, or Opendoor Technologies?
    Thinking about buying stock in Eightco Holdings, Uniqure, Atento, Red Cat Holdings, or Opendoor Technologies? PR Newswire
    20.06.23 - GlobeNewswire
    uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
    Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL Behring
    20.06.23 - PR Newswire
    CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B
    CSL Behring Announces the First Patient Has Received FDA-​Approved HEMGENIX® (etranacogene dezaparvovec-​drlb) for Hemophilia B PR Newswire
    16.06.23 - GlobeNewswire
    uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    LEXINGTON, Mass. and AMSTERDAM, June 16, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies ...

    Newssuche

    Videos

    newspaper
    18.04.24
    Technical Trading: Gold mit weiterem Potenzial
    Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »